Shares of Moderna have been volatile at the start of 2025 amid a weak growth outlook. Demand for its COVID-19 vaccine has dropped while sales of its new RSV vaccine have been sluggish. An ...
El experimento sobre la energía oscura que está sacudiendo la teoría del universo de Albert Einstein
La misteriosa fuerza llamada energía oscura, que impulsa la expansión del universo, podría estar cambiando en una forma que desafía nuestra comprensión actual del tiempo y el espacio, según ...
Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft ...
Moderna was dealt a significant blow in the patent battle over who owns the Covid-19 vaccine last week. In the U.S., the Cambridge drug and vaccine maker hit a roadblock when the Patent Trial and ...
Wesfarmers has begun experimenting with a new-look retailer in the hope of capitalising on the booming demand for beauty and skincare products that has fuelled the rapid growth of Mecca and MCoBeauty.
Un entrañable epílogo narrado por Esperanza cuenta cómo acaban todos los personajes de 'La Moderna' tres años después.
El salón de té del Madrid de los años treinta que cada tarde abría sus puertas en La 1 echa el cierre justo en su mejor momento. La serie La Moderna termina este viernes (17.05) tras 18 meses ...
Pfizer and BioNTech have convinced a U.S. Patent Office tribunal that two patents Moderna accused Pfizer-BioNtech of infringing were invalid. The companies have secured a victory in a round in their ...
Moderna has been hit by massive insider selling over the last couple of years. The stock has a 52-week high of over $170 while Moderna entered 2020 trading below $20, making insiders more likely ...
“The companies told the PTAB in the petitions that Moderna’s patents include ‘unimaginably broad claims directed to a basic idea.’” Patent Trial and Appeal Board (PTAB) docket entries ...
As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech traded blows this week with rival Moderna as dueling decisions came down in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback